MesoTV | Precision medicine and targeted therapies for mesothelioma with Dr. Hedy Kindler

Dr. Hedy Kindler of the University of Chicago Medicine joins us to discuss precision medicine and targeted therapies for the treatment of mesothelioma. Dr. Kindler explains the mechanisms of action for several molecular pathways associated with tumor growth and/or inhibition. She also discusses three specific therapeutic options available through clinical trials like CPI-0209 and olaparib (PARP inhibitors) targeted at the BAP1 tumor mutation; and the VT3989 targeting the NF2 pathway. While these treatment options are still in early clinical trial phases, they target specific known tumor mutations, which makes them more precise than traditional chemotherapy treatment.

Om Podcasten

The Mesothelioma Applied Research Foundation developed MesoTV in response to the need to cancel our annual International Symposium on Malignant Mesothelioma. In our first season we covered a number of topics, many focused on the immediate effects of Covid-19 on mesothelioma treatment. In our second season and beyond, we focus on more traditional topics such as advances in treatment, mesothelioma science, the patient and caregiver experience and quality of life. The Mesothelioma Applied Research Foundation is the only nonprofit charity organization dedicated to ending mesothelioma, and the suffering caused by this cancer, by: funding research to improve treatment options; providing treatment support and education for patients and their families; and advocating for federal funding of research.